BioHiTech Global Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioHiTech Global in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioHiTech Global stock.
View analyst ratings for BioHiTech Global or view top-rated stocks.

Wall Street analysts have given BioHiTech Global a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioHiTech Global wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BioHiTech Global saw a increase in short interest in August. As of August 13th, there was short interest totaling 1,430,000 shares, an increase of 80.2% from the July 29th total of 793,400 shares. Based on an average daily volume of 681,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 6.0% of the company's stock are sold short.
View BioHiTech Global's Short Interest.

BioHiTech Global is scheduled to release its next quarterly earnings announcement on Thursday, November 18th 2021.
View our earnings forecast for BioHiTech Global.

BioHiTech Global, Inc. (NASDAQ:BHTG) announced its quarterly earnings data on Sunday, August, 8th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.02. The business had revenue of $3.46 million for the quarter, compared to the consensus estimate of $3.18 million. BioHiTech Global had a negative net margin of 105.89% and a negative trailing twelve-month return on equity of 1,047.13%.
View BioHiTech Global's earnings history.

BioHiTech Global's stock was trading at $1.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BHTG stock has decreased by 13.5% and is now trading at $1.48.
View which stocks have been most impacted by COVID-19.

1 analysts have issued 12 month target prices for BioHiTech Global's stock. Their forecasts range from $4.00 to $4.00. On average, they expect BioHiTech Global's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price.
View analysts' price targets for BioHiTech Global or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioHiTech Global include Aspen Group (ASPU), Boxlight (BOXL), First High-School Education Group (FHS), Lixiang Education (LXEH), ATA Creativity Global (AACG), Sunlands Technology Group (STG), Zovio (ZVO), RYB Education (RYB), Tarena International (TEDU), OneSmart International Education Group (ONE), China Online Education Group (COE), Puxin (NEW), LAIX (LAIX), RISE Education Cayman (REDU) and Meten EdtechX Education Group (METX).
View all of BHTG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioHiTech Global investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), Bellicum Pharmaceuticals (BLCM), Sorrento Therapeutics (SRNE), Biocept (BIOC), Bionano Genomics (BNGO), Citius Pharmaceuticals (CTXR), Palatin Technologies (PTN), Trevena (TRVN) and T2 Biosystems (TTOO).

BioHiTech Global trades on the NASDAQ under the ticker symbol "BHTG."

BioHiTech Global's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.00%), Renaissance Technologies LLC (1.11%), Geode Capital Management LLC (0.72%), Gabelli Funds LLC (0.12%) and State Street Corp (0.09%). Company insiders that own BioHiTech Global stock include Frank E Celli, James D Chambers and Robert A Joyce.
View institutional ownership trends for BioHiTech Global.

BHTG stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC.
View insider buying and selling activity for BioHiTech Global or view top insider-selling stocks.

BHTG stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, and State Street Corp. Company insiders that have bought BioHiTech Global stock in the last two years include Frank E Celli, James D Chambers, and Robert A Joyce.
View insider buying and selling activity for BioHiTech Global or or view top insider-buying stocks.

Shares of BHTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHTG stock can currently be purchased for approximately $1.48.

BioHiTech Global has a market capitalization of $42.04 million and generates $5.88 million in revenue each year. The company earns $-11,540,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

BioHiTech Global employs 42 workers across the globe.

The official website for BioHiTech Global is www.biohitech.com.

BioHiTech Global is headquartered at 80 RED SCHOOLHOUSE ROAD SUITE 101, CHESTNUT RIDGE NY, 10977.

BioHiTech Global's mailing address is 80 RED SCHOOLHOUSE ROAD SUITE 101, CHESTNUT RIDGE NY, 10977. The company can be reached via phone at (845) 262-1081 or via email at [email protected]